Maze Therapeutics Inc.
Organization details
- Legal name
- Maze Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MAZE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001842295
Board of directors
-
Alan Colowick · DirectorSince 2025
-
Catherine A. Sohn · DirectorSince 2025
-
Charles J. Homcy · DirectorSince 2025
- Since 2025
-
Herve Hoppenot · DirectorSince 2025
-
James Brush · DirectorSince 2025
-
Jason Coloma V · Director · Chief Executive OfficerSince 2025
-
Jeffrey K. Tong · DirectorSince 2025
-
Jonathan E. Lim · DirectorSince 2025
-
Nancy C. Andrews · DirectorSince 2025
-
Neil Exter · DirectorSince 2025
-
Neil Kumar · DirectorSince 2026
-
Paula A. Johnson · DirectorSince 2026
-
Richard H. Scheller · DirectorSince 2025
-
Sekar Kathiresan · DirectorSince 2025
-
Sophie Kornowski · DirectorSince 2026
Chief executives
Director election results
Annual meeting of June 8, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.6%
-
85.8%
Board connections
13 of this board's directors also sit on 21 other boards. 21 are in the same sector.
-
BridgeBio Pharma Inc. Same sectorvia Charles J. Homcy, Neil Kumar and Richard H. Scheller
-
Alector Inc. Same sectorvia Richard H. Scheller
-
Altimmune Inc. Same sectorvia Catherine A. Sohn
-
Alumis Inc. Same sectorvia Alan Colowick
-
Bicycle Therapeutics plc Same sectorvia Herve Hoppenot
-
Boundless Bio Inc. Same sectorvia Jonathan E. Lim
-
Braveheart Bio Inc. Same sectorvia Jason Coloma V
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia Neil Kumar
-
Charles River Laboratories International Inc. Same sectorvia Nancy C. Andrews
-
Erasca Inc. Same sectorvia Jonathan E. Lim
-
Incyte Corp. Same sectorvia Herve Hoppenot
-
Jazz Pharmaceuticals plc Same sectorvia Catherine A. Sohn
-
Johnson & Johnson Same sectorvia Paula A. Johnson
-
Kyverna Therapeutics Inc. Same sectorvia Daniel K. Spiegelman
-
Myriad Genetics Inc. Same sectorvia Daniel K. Spiegelman
-
Personalis Inc. Same sectorvia Alan Colowick
-
Rapport Therapeutics Inc. Same sectorvia Jeffrey K. Tong
-
Relay Therapeutics Inc. Same sectorvia Sekar Kathiresan
-
Septerna Inc. Same sectorvia Jeffrey K. Tong
-
Spruce Biosciences Inc. Same sectorvia Daniel K. Spiegelman
-
vTv Therapeutics Inc. Same sectorvia Daniel K. Spiegelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $24,955,877
- 100 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −2,257 | $30.12 | $67,990 |
| Nov 2, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −336 | $30.91 | $10,385 |
| Nov 2, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −26,563 | $30.10 | $799,413 |
| Nov 2, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −5,345 | $31.05 | $165,977 |
| Oct 29, 2026 | Dandekar Atul Officer (CSBO) | Option exercise | +6,643 | $10.42 | $69,220 |
| Oct 29, 2026 | Dandekar Atul Officer (CSBO) | Option exercise | +857 | $10.42 | $8,930 |
| Oct 29, 2026 | Dandekar Atul Officer (CSBO) | Open-market sale | −7,500 | $32.07 | $240,532 |
| Oct 1, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Option exercise | +16,141 | $10.42 | $168,189 |
| Oct 1, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −2,593 | $27.02 | $70,073 |
| Oct 1, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −16,141 | $26.93 | $434,743 |
| Oct 1, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −31,908 | $27.02 | $862,186 |
| Sep 29, 2026 | Dandekar Atul Officer (CSBO) | Option exercise | +7,500 | $10.42 | $78,150 |
| Sep 29, 2026 | Dandekar Atul Officer (CSBO) | Open-market sale | −7,500 | $27.06 | $202,921 |
| Sep 4, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −9,705 | $26.22 | $254,465 |
| Sep 3, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −5,130 | $26.01 | $133,431 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Maze Therapeutics Inc.
Who is the CEO of Maze Therapeutics Inc.?
Jason Coloma V has been Maze Therapeutics Inc.'s Chief Executive Officer since January 2025.
How many directors are on Maze Therapeutics Inc.'s board?
Maze Therapeutics Inc.'s board has 16 directors: Alan Colowick, Catherine A. Sohn, Charles J. Homcy, Daniel K. Spiegelman, Herve Hoppenot, James Brush, Jason Coloma V, Jeffrey K. Tong, Jonathan E. Lim, Nancy C. Andrews and 6 others.
Are Maze Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Maze Therapeutics Inc. insiders made no open-market purchases and sold $25.0 million of shares in 100 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="maze-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.